Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This phase I/randomized phase II trial is studying the side effects and best dose of bevacizumab and to see how well it works when given together with or without MEDI-522 in treating patients with unresectable or metastatic kidney cancer. Monoclonal antibodies, such as bevacizumab and MEDI-522, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab and MEDI-522 may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether bevacizumab is more effective when given together with or without MEDI-522 in treating kidney cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Recurrent Renal Cell Cancer Renal Cell Carcinoma Stage III Renal Cell Cancer Stage IV Renal Cell Cancer |
Drug: etaracizumab Biological: bevacizumab |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase I and a Randomized Phase II Study of Maximal Angiogenic Blockade in Advanced Renal Carcinoma: Bevacizumab (NSC-704865) With or Without MEDI-522 (NSC-719850) |
- Maximum tolerated dose of bevacizumab , based on incidence of DLT graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 (Phase I) [ Time Frame: Up to 8 weeks ] [ Designated as safety issue: Yes ]
- Progression-free survival (Phase II) [ Time Frame: From date of registration to date of first observation of progressive disease, systemic deterioration, or death due to any cause, assessed up to 3 years ] [ Designated as safety issue: No ]
- Incidence of adverse events, graded according to NCI CTCAE version 3.0 (Phase II) [ Time Frame: Up to 3 years ] [ Designated as safety issue: Yes ]
- Overall survival (Phase II) [ Time Frame: From date of registration to date of death due to any cause, assessed up to 3 years ] [ Designated as safety issue: No ]
- Response rate according to RECIST, including confirmed and unconfirmed complete and partial responses (Phase II) [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
| Enrollment: | 142 |
| Study Start Date: | June 2008 |
| Primary Completion Date: | October 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Phase II Arm I
Patients receive bevacizumab (10mg/kg) IV over 30-90 minutes on days 1 and 15.
|
Biological: bevacizumab
Given IV
Other Names:
|
|
Active Comparator: Phase II Arm II
Patients receive bevacizumab IV as in arm I at the RPTD determined in phase I, and humanized monoclonal antibody MEDI-522 (8mg/kg) IV over 30 minutes on days 1, 8, 15, and 22.
|
Drug: etaracizumab
Given IV
Other Names:
Biological: bevacizumab
Given IV
Other Names:
|
Detailed Description:
PRIMARY OBJECTIVES:
I. To assess the appropriate dose of bevacizumab when administered with humanized monoclonal antibody MEDI-522 in patients with unresectable or metastatic renal cell carcinoma previously treated with sunitinib malate or sorafenib tosylate. (Phase I) II. To compare the progression-free survival of these patients treated with bevacizumab with versus without humanized monoclonal antibody MEDI-522. (Phase II) III. To evaluate the qualitative and quantitative toxicities of bevacizumab and humanized monoclonal antibody MEDI-522 in these patients. (Phase II) IV. To estimate overall survival and RECIST response rate (i.e., confirmed and unconfirmed, complete and partial responses) in both treatment arms. (Phase II)
OUTLINE: This is a multicenter, phase I, dose-escalation study of bevacizumab followed by a randomized phase II study.
PHASE I: Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and humanized monoclonal antibody MEDI-522 IV on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity until the recommended phase II dose (RPTD) of bevacizumab is determined.
PHASE II: Patients are stratified according to the number of prior treatment regimens for renal cell carcinoma (1 vs 2) and whether there is a clear cell component (yes vs no). Patients are randomized to 1 of 2 treatment arms:
ARM I: Patients receive bevacizumab (10 mg/kg) IV over 30-90 minutes on days 1 and 15.
ARM II: Patients receive bevacizumab IV as in arm I at the RPTD determined in phase I, and humanized monoclonal antibody MEDI-522 (8 mg/kg) IV over 30 minutes on days 1, 8, 15, and 22.
In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed periodically for up to 3 years.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria:
- Histologically or cytologically confirmed renal cell carcinoma
- Metastatic or unresectable disease
- Must have received prior sunitinib malate or sorafenib tosylate for metastatic or unresectable disease
- Measurable disease
- No soft tissue disease that has been irradiated within the past 2 months
- More than 6 months since prior and no concurrent treated or untreated brain metastases
- Stable, treated brain metastases allowed provided they remained stable for more than 6 months
- Patients with clinical evidence of brain metastases must have a negative brain CT or MRI scan for metastatic disease
- Zubrod performance status 0-1
- Urine protein:creatinine ratio =< 0.5 OR urine protein < 1,000 mg by 24-hour collection
- Not be pregnant or nursing
- Fertile patients must use effective contraception during and for at least 6 months after completion of study therapy
- No serious or non-healing wound, ulcer, or bone fracture
- No clinically relevant bleeding diathesis or coagulopathy
- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
- No significant traumatic injury within the past 28 days
- No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
- No other prior malignancy, except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years
- No New York Heart Association class II-IV congestive heart failure
- No unstable symptomatic arrhythmia requiring medication
- Chronic, controlled arrhythmias (e.g., atrial fibrillation or paroxysmal supraventricular tachycardia) allowed
- None of the following cardiovascular conditions within the past 6 months: Arterial thrombosis, Unstable angina, Myocardial infarction, Cerebrovascular accident
- Must have controlled blood pressure, defined as systolic blood pressure (BP) =< 160 mm Hg and/or diastolic BP =< 90 mm Hg
- More than 7 days since prior core biopsy
- At least 14 days since completion of prior therapy and recovered
- At least 28 days since prior radiotherapy and recovered
- No prior radiotherapy to >= 25% of bone marrow
- No more than two prior systemic regimens for renal cell carcinoma (including adjuvant treatment)
- No prior bevacizumab or humanized monoclonal antibody MEDI-522
- No major surgical procedure or open biopsy within the past 28 days
- No concurrent need for a major surgical procedure
- Concurrent full-dose anticoagulation with warfarin allowed provided INR is between 2-3
- Concurrent low molecular weight heparin allowed
- No clinically significant vascular disease (e.g., aortic aneurysm or history of aortic dissection)
Contacts and Locations| United States, California | |
| Fremont - Rideout Cancer Center | |
| Marysville, California, United States, 95901 | |
| UC Davis Comprehensive Cancer Center | |
| Sacramento, California, United States, 95817 | |
| United States, Michigan | |
| University of Michigan University Hospital | |
| Ann Arbor, Michigan, United States, 48109 | |
| United States, North Carolina | |
| Presbyterian Hospital | |
| Charlotte, North Carolina, United States, 28204 | |
| United States, Texas | |
| Southwest Oncology Group | |
| San Antonio, Texas, United States, 78245 | |
| Principal Investigator: | Christopher Ryan | Southwest Oncology Group |
More Information
No publications provided
| Responsible Party: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00684996 History of Changes |
| Other Study ID Numbers: | NCI-2009-01099, S0717, CDR0000596555, U10CA032102 |
| Study First Received: | May 24, 2008 |
| Last Updated: | April 1, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Carcinoma Carcinoma, Renal Cell Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Kidney Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Kidney Diseases Urologic Diseases |
Antibodies Antibodies, Monoclonal Bevacizumab Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Growth Inhibitors Antineoplastic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 23, 2013